Table 7

Studies reporting comorbidity status as possible predictor of functional outcome after THA

 MeasurementFU periodSignificance 
Author, yearGradeN of ptstool(months)level (p value)AssociationPredictor level of measurement
Quintana, 2009Moderate788WOMAC PFST (6 m)NANoCat (3)
SF-36 PFNA1: 0 comorbidities 2: 1–2 comorbidities 3: >2 comorbidities
Mahomed, 2002Moderate103WOMAC PF+PST (6 m)<0.05NegCont
(number of comorbidities)
Moran, 2005Moderate749HHSST (6 m)NANegDich
ST (18 m)(presence of coronary heart disease and
previous thromoembolism)
Stevens, 2012Moderate653WOMACST (12 m)0.01NegCat (3)
1: 0 comorbidities 2: 1–2 comorbidities 3: >2 comorbidities
Clement, 2010High1312OHSST (12 m)0.01NegCont
SF-12(number of comorbidities)
Dowsey, 2014High835HHSST (12 m)0.0001NegCont
(age-adjusted CCI)
Wang, 2010Moderate97WOMACST (16.8 m)0.0246NegDich
(1: >0 comorbidities 2: 0 comorbidities)
Jones, 2012Moderate231WOMACLT (36 m)0.012NegDich
(1; 0 cardiac diseases
2: >0 cardiac diseases)
Bischoff, 2004Moderate922WOMAC PFLT (36 m)NANegDich
(1; >2 chronic diseases
2. 0–1 chronic diseases)
Smith, 2012Moderate1683HHSLT (36 m)<0.001NegCont
(ASA grade)
Gandhi, 2010Low636WOMACLT (39 m)<0.05NegCont
SF-36 PF(number of comorbidities)
Nilsdotter, 2003Low211WOMAC PFLT (42 m)0.08NoDich
(1: >1 comorbidities 2: 0–1 comorbidities)
Judge, 2013High1431OHSLT (60 m)0.001NegCont
(number of comorbidities)
  • All significant results are bold.

  • BMI, body mass index; Cat, categorical; CCI, Charlson comorbidity index; Cont, continuous; Dich, dichotomous; FU, follow-up; HHS, Harris Hip Score; LEFS, Lower Extremity Functional Scale; LT, long-term; N of pts, number of patients; NA, not applicable; Neg, negative; OHS, Oxford Hip Score; Pos, positive; SF-36 PF, Short Form 36 physical function; ST, short-term; THA, total hip arthroplasty; WOMAC, Western Ontario and Mcmaster Universities Osteoarthritis Index.